James Gavin III, MD, PhD
Clinical Professor of Medicine
Emory University School of Medicine
Atlanta, Georgia
Clinical Professor of Medicine
Indiana University School of Medicine
Indianapolis, Indiana
Related Videos
Video
What is the importance of postprandial hyperglycemia (PPG) and glucose excursions as a management metric and what are the implications for selecting GLP-1 RAs?
Video
Can you provide clinical profiles where there is a strong rationale to move from a regimen consisting of metformin and SGLT2 inhibitor, to a fixed ratio combination of a basal insulin plus GLP-1 RA?
Video
What is the rationale, therefore, of combining GLP-1 RAs and basal insulin into fixed ratio combination agents?
Video
In what setting and in what patient profiles do GLP-1 RAs make most sense? What degrees of HA1c reduction are seen?
Video
Why, in both ADA and AACE guidelines statements, do GLP-1 receptor agonists represent a foundational approach for management of T2D?